Compare Autodesk Inc (ADSK) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autodesk Inc vs Twist Bioscience Corp — how do they compare? Autodesk Inc trades at $247.48 (market cap $53.12B), while Twist Bioscience Corp trades at $123.76 (market cap $7.72B). The key difference: Autodesk Inc is far larger — about 6.9× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Autodesk Inc nearer its low. Which is the better fit depends on your goals.
| ADSK | TWST | |
|---|---|---|
Market Cap | $53.12B | $7.72B |
Sector | Technology | Health |
52-Week High | $326.79 | $124.88 |
52-Week Low | $187.72 | $24.16 |
Enterprise Value | $52.92B | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $247.39, down 3.39% in the latest session, but maintains strong fundamentals with consistent earnings beats and robust revenue growth. The stock shows a bullish technical trend with moving averages supporting upside momentum, while RSI levels indicate potential overbought conditions. Recent financial performance demonstrates expanding profit margins and healthy cash flow generation, supported by the company's dominant position in design software markets.
The outlook remains positive with analyst consensus favoring continued growth, though elevated valuation multiples and competitive pressures present risks. Upside potential exists toward the $302.23 consensus price target, supported by strong institutional backing and strategic AI investments. Key risks include market volatility and execution challenges in maintaining premium valuation levels.
Twist Bioscience (TWST) trades at $123.76, down 0.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, with 2025 revenue at $376.57 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights an upsized $300 million public offering and an analyst upgrade, contributing to positive sentiment.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, negative cash flow, and high valuation ratios pose significant risks. Investors should weigh the growth trajectory against the path to profitability and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
